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Background: Laboratory diagnosis of Lyme neuroborreliosis (LNB) is partly based on the detection of intrathecal
Borrelia burgdorferi–specific antibody production (increased antibody index (AI)). However, AI can be negative in
patients with early LNB and, conversely, can remain elevated for months after antibiotic treatment. Recent studies
suggested that the chemokine CXCL13 in the cerebrospinal fluid (CSF) is a biomarker for active LNB. Also, CSF
neopterin-level determination has been used to assess the degree of neuroinflammation in a wide variety of
diseases.
Methods: CXCL13 concentrations were analyzed in CSF samples of 366 retrospectively identified individuals. The
samples represented pretreatment LNB (38 patients), non-LNB comparison patients, tick-borne encephalitis, central
nervous system (CNS) varicella zoster virus infection, CNS herpes simplex virus infection, CNS HHV6 infection, CNS
enterovirus infection, and untreated neurosyphilis. The panel included also samples from patients with multiple
sclerosis and other neuroinflammatory conditions. Of the LNB patients, 24 posttreatment CSF samples were
available for CXCL13 analysis. Neopterin concentrations were determined in a subset of these samples.
Results: The CXCL13 concentrations in CSF samples of untreated LNB patients were significantly higher
(median, 6,480 pg/ml) than the concentrations in the non-LNB group (median, <7.8 pg/ml), viral CNS infection
samples (median, <7.8 pg/ml), or samples from patients with noninfectious neuroinflammatory conditions (median,
<7.8 pg/ml). The use of cut-off 415 pg/ml led to a sensitivity of 100% and specificity of 99.7% for the diagnosis of
LNB in these samples. CSF CXCL13 median concentrations declined significantly from 16,770 pg/ml before to
109 pg/ml after the treatment.
CSF neopterin concentration was significantly higher among the untreated LNB patients than in the non-LNB
group. The use of neopterin concentration 10.6 nM as the cut-off led to a sensitivity of 88.6% and a specificity of
65.0% for the diagnosis of LNB. The CSF neopterin concentrations decreased statistically significantly with the
treatment.
Conclusions: These results clearly indicate that highly elevated CSF CXCL13 levels are strongly associated with
untreated LNB. CXCL13 outperformed neopterin and appears to be an excellent biomarker in differentiating LNB
from viral CNS infections and from other neuroinflammatory conditions.
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Lyme neuroborreliosis (LNB) is a tick-borne infection of
the nervous system caused by the Borrelia burgdorferi
sensu lato spirochetes [1,2]. The diagnosis of LNB is
based on a combination of anamnestic, clinical, and la-
boratory findings. According to the guidelines by Euro-
pean Federation of Neurological Societies, the laboratory
diagnosis of LNB is based specifically on the detection of
intrathecal Borrelia burgdorferi–specific antibody pro-
duction (positive antibody index (AI)) [3]. Unfortunately,
in some cases, the intrathecal antibody production is un-
detectable for several weeks after the onset of symptoms,
leading to false-negative results. Conversely, AI may re-
main positive for months or even years after treatment,
hampering the use of AI determination in later episodes
of suspected LNB [4].
CXCL13 is a member of the CXC chemokine family. It
selectively attracts B lymphocytes and helper T cells via
the chemokine receptor CXCR5 [5]. In addition to being
a chemokine involved in the development and mainten-
ance of secondary lymphoid organs, CXCL13 is pro-
duced during inflammation also in nonlymphoid tissues,
such as the central nervous system (CNS), where it func-
tions as an attractor of B cells. Thus, it is understandable
that CXCL13 levels in the CSF of LNB patients increase
early in the course of the infection before any detectable
antibody production, and CXCL13 in CSF has been sug-
gested to be an early marker of LNB [6-12]. Also, the
CXCL13 concentration in the CSF of LNB patients has
been shown to decline rapidly after antibiotic treatment
[6,13].
Neopterin is a pteridine derived from guanosine tri-
phosphate. This proinflammatory factor is produced
mainly by monocytes–macrophages and dendritic cells.
Human endothelial cells and B-lymphocytes have been
reported to be a source of neopterin. The proinflamma-
tory cytokine interferon-γ is the main stimulus for neop-
terin production. Neopterin concentration in serum and
CSF has been suggested to be a marker of disease activ-
ity in a wide range of infectious and inflammatory dis-
eases [14-17].
The aim of the present study was to evaluate CXCL13
in comparison to neopterin as biomarkers for LNB and
for monitoring response to therapy.
Methods
Patient samples
Patients were identified retrospectively from the labora-
tory information-management system of our laboratory.
The patients were diagnosed according to the current
Finnish guidelines, and the diagnoses were obtained
from the patient records. All CSF samples were collected
with informed consent from patients suspected to have a
neurologic disease as a part of routine clinical practice.All samples were coded, and strict anonymity was
maintained throughout the study. According to the
Finnish Medical Research Act (No. 488/1999), Chapter 1,
Sections 1, 2, and 3, the research in the present study is
not medical research, and thus, it was not necessary to
obtain a separate approval from the local Ethics Commit-
tee to use the samples in the assays of the present study.
Altogether, CSF samples from 366 individuals were avail-
able for the study (Figure 1). After CSF-sample collec-
tion, the samples were sent at room temperature to our
laboratory, where they were first stored at 4°C until bor-
relia serology was performed. After the serologic assays
were completed, the samples were stored at −20°C until
the chemokine analyses of the present study were initi-
ated (length of storage from weeks up to 3 years).
LNB patients were diagnosed using the following
criteria: 1) The patients had symptoms consistent with
LNB, 2) other relevant diagnoses were excluded, 3) there
was mononuclear pleocytosis in CSF of the patients
with >5/ μl mononuclear cells and <100/ μl erythrocytes,
4) CSF samples were at a positive level for borrelia
specific antibodies of IgM and/or IgG class as analysed
by an in-house whole borrelia antigen (B. burgdorferi
B31 sonicate) ELISA and/or with the commercial
C6-peptide based assay (C6 Lyme ELISA; Immunetics
Boston, Massachusetts, USA) using a 1:5 dilution of the
CSF [18], and 5) intrathecal antibody production was
observed as indicated by a positive (>0.3) IgM and/
or IgG antibody index (AI) using the IDEIA Lyme
Neuroborreliosis kit (Oxoid, Basingstoke, UK).
Laboratory analyses
CXCL13 levels in 390 CSF samples (including 24 post-
treatment LNB samples) were measured by using a human
CXCL13 kit (Quantikine; R&D Systems, Minneapolis,
MN, USA). The frozen samples were allowed to thaw at
room temperature. The analyses were performed accord-
ing to the instructions of the manufacturer. Samples with
concentrations over the standard curve of the assay
(>500 pg/ml) were further diluted 10 to 100 times with
the calibration diluent buffer of the kit, and reanalyzed.
Between the first analysis and the reanalysis, the samples
were stored at −20°C.
Neopterin concentrations in CSF samples were mea-
sured by using Neopterin ELISA kit (IBL International
GmbH, Hamburg, Germany) according to the instruc-
tions of the manufacturer. For neopterin-concentration
analysis, 262 CSF samples (including 21 posttreatment
LNB samples) were available.
Tick-borne encephalitis (TBE)-specific antibodies were
measured by using SERION ELISA classic TBE Virus
IgG/IgM kits (Institut Virion\Serion GmbH, Würzburg,
Germany). For viral nucleic acid testing, total nucleic acid
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Figure 1 An overview of CSF samples in which CXCL13 concentrations were analyzed in the study. Neopterin levels were measured in
262 of the samples.
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Enterovirus RNA was detected with RT-PCR, as described
previously [19]. DNA for human herpes viruses (varicella
zoster (VZV), herpes simplex (HSV) −1 and −2, and human
herpesvirus 6 (HHV-6)) was detected with individual qPCRs
[20]. The performance of all of the PCR assays has been vali-
dated with appropriate proficiency-testing panels from Qual-
ity Control for Molecular Diagnostics (Glasgow, Scotland).
The single neurosyphilis case was diagnosed by using
the following assays: Enzygnost Syphilis competitive en-
zyme immunoassay (Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany) and Treponema
pallidum hemagglutination assay (TPHA) (Cellognost-
Syphilis H; Siemens) were used for the detection of
treponemal antibodies, and VDRL (Venereal Disease Re-
search Laboratory) carbon antigen agglutination test
(Oxoid) was used to detect nontreponemal antibodies.
Statistical analyses
Statistical analyses were performed by using IBM SPSS
Statistics 22. To test for the normality of the data, the
Kolmogorov-Smirnov test was applied. Differences in
CXCL13 and neopterin concentrations between groups
were analyzed by using the Kruskal-Wallis test followed
by single pairwise comparisons with the Mann–Whitney
U test and Bonferroni corrections. Wilcoxon signed-
rank test was used to compare concentrations before
and after treatment. Correlations were done by using
Spearman rank-order correlations. P values of <0.05
were considered significant.
The CSF quotients of mononuclear cells, CXCL13, or
neopterin before and after treatment among the sample
pairs (where the posttreatment sample was collected at
the end of the treatment) were calculated as follows:
pretreatment CSF sample value divided by the posttreat-
ment CSF sample value regarding CSF mononuclear
cells, CXCL13, and neopterin concentrations.Results
CSF samples from 366 retrospectively identified individ-
uals were available for the present study (Figure 1). Of
these samples, 38 were borrelia antibody-positive pre-
treatment samples, of which 31 were from confirmed
LNB patients. Seven patients did not fulfill all the LNB
criteria presented in Materials and methods, and thus
they represented probable LNB cases. AI was negative or
not done in six of the probable patients, and in one pa-
tient, the CSF mononuclear cell count was below 5/μl.
Of the 31 confirmed LNB patients, 24 posttreatment
CSF samples were available for CXCL13, and 21, for
neopterin determinations, respectively. Nineteen of the
posttreatment samples available for CXCL13 analysis
were collected 2 to 4 weeks after the pretreatment sam-
ples, whereas in five cases, the second sample was col-
lected several months (108 to 223 days) after the first
sample. For neopterin measurement, 16 posttreatment
samples collected at the end of treatment and five sam-
ples collected months after the treatment were available.
All 38 LNB patients were borrelia antibody positive in
the serum, as determined by the in-house whole-borrelia
antigen ELISA [21], and/or with the C6-peptide-based
assay (C6 Lyme ELISA; Immunetics) (data not shown).
The presenting symptom in 30 of the LNB patients
was radiculitis or pain radiating to the upper or lower
limbs or to the trunk. Nineteen patients had facial nerve
paralysis. Thirteen patients had both symptoms. In
addition, some patients had intermittent or continuous
headache, eye manifestations, dizziness, or paresis. The
median duration of symptoms before the first CSF sam-
ple was 30 days, with the range from zero to 120 days.
LNB patients were treated with either intravenous ceftri-
axone, oral doxycycline, or with a combination of both
of these drugs. The non-LNB group included 239 CSF
samples that were sent to our laboratory for borrelia
antibody analysis, and that were found to be borrelia




































LNB 38 66 (3–80) 16/22 37/1 37/1 29/3/6 104 (0–1516) 21/4 1034 (454–3148) 30 (0–120) 11 2 19 30
Treated
LNB 24 64 (34–79) 8/16 22/2 18/6 19/4/1 35 (0–120) 10/0 601 (267–1597) NA
j NA NA NA NA
Non-LNB 239 50 (1–91) 133/106 0/239 NDk ND NKl NK NK NK NK NK NK NK
aCSF antibodies to B. burgdorferi s.s B31 whole cell antigen.
bCSF antibodies to C6-peptide.
cIntrathecal antibody production index.
dCells/μl, mononuclear cell count.
eOC-bands, oligoclonal bands in CSF.
fDuration of symptoms before first CSF sampling.
gObserved tick bite.
hObserved erythema migrans.
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patients and the non-LNB subjects are listed in Table 1.
Samples for the comparison groups were selected
based on the conception that the associated clinical man-
ifestations are potential differential diagnostic options for
LNB. The comparison samples from patients with
other CNS infections included (a) ten CSF samples from
patients with TBE, (b) 19 samples from patients with
CNS VZV infection; (c) 14 samples from patients with
CNS HSV infection; (d) three samples from patients
with CNS HHV-6 infection, (e) eight samples from patients
with CNS enterovirus infection; and (f) one sample from
an untreated neurosyphilis patient. Also, the comparison
sample panel included 34 samples from patients with con-
firmed (19) or suspected (8) multiple sclerosis (MS), or
with other neuroinflammatory conditions (7). In all these
34 patients, CSF oligoclonal (OC) bands were detected.
CXCL13 concentrations in CSF of different patient groups
and in non-LNB samples
The concentrations of CXCL13 in CSF of all untreated
LNB patients ranged from 424 to 158,000 pg/ml, with
the median of 6,480 pg/ml (Figure 2). Among the seven































Figure 2 CXCL13 concentrations in the LNB and comparison CSF sam
the lowest standards of the assay (<7.8 pg/ml). If more than eight samples
indicates the number of such samples. The arrow indicates the median con
with the Mann–Whitney U test and Bonferroni corrections were used for stranged from 498 to 8,600 pg/ml, and among the non-
LNB samples, from <7.8 to 153 pg/ml, with the median
of <7.8 pg/ml. The difference in CSF CXCL13 concen-
trations between the untreated LNB patients and the
non-LNB group was statistically significant (P < 0.001).
Among the samples of the patients with viral CNS infec-
tions, the CSF CXCL13 concentrations ranged from <7.8
to 406 pg/ml, and the statistical difference between these
viral CNS infection samples and the LNB samples was
highly significant, with P values of 0.0013 or less in all
cases. CSF CXCL13 concentrations in the 34 samples
from patients with noninfectious neuroinflammatory
conditions ranged from <7.8 to 280 pg/ml, which was
also significantly different (P < 0.001) from the CXCL13
levels of LNB samples.
Neurosyphilis caused by the spirochete Treponema
pallidum subsp. pallidum appears to be the only other
disease among the conditions investigated in this study
that leads to markedly increased CSF CXCL13 concen-
tration. CXCL13 in the CSF sample of the single neuro-
syphilis patient was 37,000 pg/ml. These results clearly
indicate that highly elevated CSF CXCL13 levels are asso-
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were below the lowest standard, the figure below the black diamonds
centration. Kruskal-Wallis test followed by single pairwise comparisons
















Figure 3 ROC curve analyses of CSF CXCL13 and neopterin levels were performed to obtain the best cut-off values that would
discriminate between LNB patients and the comparison groups.
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(ROC) curve analysis (LNB pretreatment samples against
all comparison groups) shown in Figure 3 and also from
the data presented in Figure 2 that the diagnostic perform-
ance of CSF CXCL13 determination with a cut-off 415
pg/ml results in nearly perfect discrimination between the
LNB patients and other groups in this sample material.
The use of this cut-off led to sensitivity of 100% and speci-
ficity of 99.7% for the diagnosis of LNB.
Neopterin concentrations in CSF samples of the different
groups
Neopterin concentrations were analyzed in the previ-
ously mentioned sample groups, although in most of the
groups, the number of samples available for neopterin
analysis was somewhat smaller than the number of sam-
ples in CXCL13 analysis (Figure 4). Neopterin concen-
tration was significantly higher (P < 0.001) among the
untreated LNB patients (median, 26.6 nM) than in the
non-LNB group (median, 6.3 nM). Conversely, and in
contrast to CSF CXCL13 levels, neopterin concentra-
tions were widely scattered over the entire measuring
range in LNB, TBE, VZV, and HSV samples. In fact, CSF
neopterin levels were significantly higher among the
VZV (P < 0.05) and HSV (P < 0.01) infected patients than
among LNB patients. In the single neurosyphilis sample,
the neopterin concentration was 92.2 nM. Among thesamples of the other neuroinflammatory patients, CSF
neopterin levels were uniformly low.
ROC curve analysis (LNB pretreatment samples against
all comparison groups) was performed also with the neo-
pterin data, and the result is shown in Figure 3. The use of
neopterin concentration 10.6 nM as the cut-off led to
sensitivity of 88.6% and specificity of 65.0% for the diag-
nosis of LNB.
Effect of antibiotic treatment on CXCL13 and neopterin
concentrations in CSF of LNB patients
Twenty-four posttreatment CSF samples were available for
CXCL13 analysis from the confirmed LNB cases. Nineteen
of the samples were collected at the end of or right after
the antibiotic treatment. Five samples were collected several
months after the first sample. The decline in CSF CXCL13
levels along the treatment was striking; the median concen-
tration before the treatment among the 24 samples was
16,770 pg/ml (average, 19,730 pg/ml), and after the treat-
ment, 109 pg/ml (average, 138 pg/ml) (Figure 5). The
decline was statistically significant (P < 0.001). Among the
five posttreatment samples that were collected only months
after the treatment, CXCL13 was <7.8 pg/ml in four
samples and 20.6 pg/ml in one sample.
Also, the CSF neopterin concentrations (21 posttreat-
ment samples; 16 samples collected at the end of or right








































Figure 4 Neopterin concentrations in the LNB and comparison CSF samples. Black diamonds indicate CSF samples with concentration
above the highest standards of the assay (>111 nM). The arrow indicates the median concentration. Kruskal-Wallis test followed by single pairwise
comparisons with Mann–Whitney U test and Bonferroni corrections were used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001.
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along with the treatment (P < 0.001). The median concen-
tration before the treatment was 47.9 nM(average, 51.1
nM) and after the treatment, 7.5 nM (average, 8.0 nM).
Correlations among CSF parameters in LNB patients
The correlations of CSF parameters were analyzed among


















Figure 5 CXCL13 (left) and neopterin (right) concentrations in CSF sa
Twenty four samples (21 for neopterin) of which 19 (16 for neopterin) were
several months after the first sample were available for the analyses. The ar
was used to compare concentrations before and after treatment. ***P < 0.0correlations between the quotients of CSF mononuclear
cells, CSF CXCL13, or CSF neopterin before and after
treatment are shown in Figure 6F-H. No statistically
significant correlation was observed among the different
CSF parameters. In the analysis of CSF neopterin
concentration versus CSF cell count (Figure 6B), a trend
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mples of LNB patients before and after antibiotic treatment.
collected at the end of or right after the treatment, and five samples
row indicates the median concentration. Wilcoxon signed-rank test
01.
Figure 6 Correlations among CSF parameters in LNB patients. (A) CSF CXCL13 concentration in untreated LNB patients plotted against CSF
cell count. (B) CSF neopterin concentration in untreated LNB patients plotted against CSF cell count. (C) CSF CXCL13 concentration in untreated
LNB patients plotted against duration of symptoms before CSF sampling. (D) CSF neopterin concentration in untreated LNB patients plotted
against duration of symptoms before CSF sampling. (E) CSF CXCL13 concentration in untreated LNB patients plotted against CSF neopterin
concentration. (F) CSF CXCL13 quotient (see Statistical analyses for definition) plotted against neopterin quotient. (G) CSF quotient of
mononuclear cells plotted against CXCL13 quotient. (H) CSF quotient of mononuclear cells plotted against neopterin quotient. No statistically
significant correlations were observed.
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The early diagnosis of LNB can be difficult because the
intrathecal production of Borrelia burgdorferi-specific
antibodies may be absent in the beginning of the disease[22]. The chemokine CXCL13 is a promising biomarker
with a high sensitivity and specificity for early untreated
LNB also in atypical cases [23]. Elevated concentrations
of CXCL13 in the CSF may appear several days before
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Intrathecal borrelia-specific antibody production may
persist for years after successful treatment [4], whereas
the levels of CXCL13 decrease rapidly after antibiotic
treatment, and hence it might be suitable for monitoring
of treatment response, and distinguishing an active infec-
tion from a past infection [24]. It has also been suggested
that CSF CXCL13 may be a marker of disease duration in
LNB rather than a marker of disease activity [7].
In the present study, the level of CSF chemokine
CXCL13 was highly elevated in patients with untreated
LNB and decreased rapidly after treatment. At the time
of diagnosis, the levels of CXCL13 varied from 424 to
158,000 pg/ml (median, 6,480 pg/ml) in LNB patients. In
non-LNB patients, the levels of CXCL13 varied from <7.8
to 153 pg/ml. The single patient with neurosyphilis had a
CXCL13 level of 37,000 pg/ml. Neurosyphilis is known
to elevate the level of CXCL13 in the CSF [7,8]. At the
time of diagnosis, the levels of CXCL13 in the CSF were
significantly higher in LNB patients than in comparison
groups. The diagnostic sensitivity of CSF CXCL13 meas-
urement was 100%, and specificity was 99.7% when using
415 pg/ml as the cut-off. Thus, our results strengthen
previous findings that CXCL13 is an excellent tool for
the diagnostics of early LNB.
Previous studies reported different cut-off values of
CSF CXCL13 in LNB ranging from 61 pg/ml to 1,229
pg/ml [6-8,12,13]. The difference among cut-offs of these
studies might reflect variability in the analytic test used
for the chemokine measurement. However, in these stud-
ies, and in the present study, CXCL13 levels were mea-
sured by using the same commercial kit. The intercenter
variability may also be due to, for example, variation in
the comparison groups. When determining the sensitivity
and specificity of a test, it is essential to use relevant
comparison samples that is, in the case of LNB, compari-
son subjects should include patients with locally encoun-
tered diseases that cause symptoms similar to those
caused by LNB. Thus, it is also advisable to use locally
determined CSF CXCL13 cut-offs until a universally ac-
cepted cut-off level has been established.
The LNB patients were treated either with intravenous
ceftriaxone, oral doxycycline, or with a combination of
both, according to Finnish practices and international
recommendations [25]. Levels of CSF CXCL13 decreased
rapidly after antibiotic treatment. Nineteen of 24 post-
treatment samples were collected 3 to 4 weeks after the
first sample and institution of the antibiotic treatment. In
five of 24 cases, the second CSF sample was taken 108 to
225 days after the first sample. The reason for the late
control-sample collection was residual posttreatment
symptoms. However, reinfections or relapses, as based on
subjective symptoms, or serum or laboratory parameters,
were not identified during the follow-up. Also in the latecontrol-sample group, the levels of CXCL13 remained
low. It remains to be investigated whether CSF CXCL13
levels increase again after a reinfection or relapse. Also,
additional studies are needed to correlate the change in
CSF CXCL13 levels with subjective and objective recovery
after LNB treatment.
Elevation of CSF neopterin is a marker of an acute or
active CNS inflammation, but it is not specific to any
particular disease [26]. Neopterin has been suggested as
a useful marker for the evaluation of the posttherapeutic
outcome in patients with sleeping sickness caused by
Trypanosoma brucei gambiense infection [27]. In our
study, the levels of neopterin were high in a number of
CSF samples, including those obtained from LNB pa-
tients, but also in samples from patients with viral (espe-
cially TBE, VZV, and HSV) CNS infections. However,
low CSF neopterin concentrations were also observed in
the same groups. Thus, neopterin is neither a sensitive
nor a specific marker in these conditions. The levels of
CSF neopterin decreased after antibiotic treatment in
LNB patients. We conclude that because of the low sen-
sitivity and specificity, neopterin measurements cannot
be recommended as a tool for purposes of diagnosis of
LNB or for assessment of LNB treatment outcome. Be-
cause CSF neopterin levels were uniformly low in the
samples of the patients with MS or other neuroinflam-
matory diseases, CSF neopterin may in some cases help
in distinguishing neuroinflammatory conditions from
neuroinfection.
In statistical analyses, no significant correlations were
found between different CSF parameters in the pretreat-
ment LNB samples, or in the quotients of CSF mono-
nuclear cells, CXCL13, or neopterin before and after the
treatment. Only in the correlation of CSF neopterin con-
centration versus CSF cell count was a trend noted to-
ward significance with P value 0.057. In a previous
study, a significant correlation occurred between CSF
mononuclear cells and CXCL13 [13]. The reason for this
correlation remains unclear.
Some limitations exist in the current study. First, be-
cause of the nature of the study, the samples were
mainly from preselected hospital patients, and no CSF
samples of healthy people were included. The borrelia
antibody-negative non-LNB samples were collected dur-
ing diagnostic workup from patients with some degree
of neurologic symptoms, and thus they do not represent
healthy people. Also, the untreated LNB patients were
older (median age, 66 years) than non-LNB subjects
(median age, 50 years). However, CSF CXCL13 concen-
trations among these non-LNB samples were uniformly
low, highlighting the specificity of elevated CSF CXCL13
as a biomarker for LNB.
Second, seven patients represented probable LNB
cases based on normal or not determined AI, or on lack
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antibodies against Borrelia burgdorferi in the CSF and
serum, and their CSF CXCL13 concentrations ranged
from 498 to 8,600 pg/ml, suggesting also that these pa-
tients were most likely true LNB patients. Also, the clin-
ical manifestations among the probable LNB patients
(radiculitis and/or facial nerve paralysis) fit in with the
diagnosis of LNB. No follow-up samples were available
of the probable LNB patients, who had normal AI in the
pretreatment CSF sample, and thus it remains unsolved
whether the AI would have turned positive later during
the infection.
Third, sample storage at −20°C before testing may in
principle decrease levels of CXCL13, and thus result in
falsely low concentrations [12]. Some of the LNB patient
samples and all the comparison samples had been stored
frozen before the cytokine analyses. In one study, the
duration of storage of a sample did not result in lower
levels of CXCL13 in the LNB group, as the concentra-
tion of CXCL13 did not decrease during storage for up
to 5 years [8]. We also performed a control assay in
which one CSF sample was divided in five aliquots that
were frozen and thawed up to 5 times. The procedure
did not influence the levels of CXCL13 (Hytönen et al.
unpublished data).
Fourth, no CSF samples of patients with purulent
meningitis, CNS lymphoma, cryptococcosis, African
trypanosomiasis, or HIV were among the comparison
samples. Previously, it was reported that CSF CXCL13
may be elevated in patients with these conditions
[6,8,13,28]. However, we selected the comparison sam-
ples especially from patients who had diseases that are
potential differential diagnostic options for LNB in
Finland. Meningitis caused by typical bacteria is usually
easy to discriminate from LNB because of the clinical
presentation, serum inflammatory markers and CSF
white cell count, granulocytic differential count, micros-
copy, and bacterial culture. Thus, purulent meningitis
samples were not studied. Samples from CNS lymphoma
and neurologically symptomatic HIV patients were not
available.
Conclusions
The results of the present study suggest that CSF neo-
pterin is an insensitive and unspecific biomarker that is
not suitable for diagnostics of LNB, but it may have role
in distinguishing neuroinfective diseases from neuroin-
flammatory states. In contrast, CSF CXCL13 appears to
be an excellent biomarker in differentiating LNB from
viral CNS infections and from other neuroinflammatory
conditions when locally determined cut-offs are used. It
is also a useful tool for follow-up of LNB patients after
antibiotic treatment. However, CSF CXCL13 results
should be interpreted in conjunction with intrathecalborrelia antibody production, CSF pleocytosis, and ideally
also borrelia nucleic acid amplification result. Limited in-
formation is available of CSF CXCL13 levels in chronic
LNB [7], or in relapses and reinfections. Further studies
are required to correlate the decline in CSF CXCL13
levels with clinical recovery after LNB treatment.
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